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StllTlillary 
The etiopathogenesis of focal and segmental glomerular sclerosis (FGS) remains unknown. Using 
a new animal model for FGS (FGS mouse), we demonstrate here that bone marrow transplantation 
from normal mice to FGS mice with a high grade of proteinuria (+ + +) ameliorates FGS, and 
that the transplantation of bone marrow cells or purified hemopoietic stem cells (HSCs) from 
FGS mice induces FGS in normal mice. These findings strongly suggest that FGS is a stem cell 
disorder; the abnormalities may be genetically programmed at the level of HSCs. 
F 
~ocal and segmental glomerular sclerosis (FGS) is a condi- 
tion characterized by the presence of  localized or segmental 
sclerosis in some glomerular tufts (1). FGS is resistant to the 
therapy of steroid hormones or immunosuppressive agents. 
Animal models of FGS have been induced by chemicals 
or other artificial means (2-6). Spontaneous animal models 
for FGS have also been reported, but most are found in rats 
(7-9). A model mouse of FGS has recently been established 
from the F5 offspring of the crossing between CBA/Nga 
and RFM/Nga mice (10). The mice show high levels ofpro- 
teinuria after 40 d of age. The abnormality appears to be con- 
trolled by two pairs of autosomal recessive  genes. 
We have recently found that bone marrow transplantation 
(BMT) or BMT plus bone grafts (to recruit donor-derived 
stromal cells) can be used to prevent and treat both systemic 
and organ-specific autoirnmune diseases in NOD, (NZB  x 
NZW)F1,  MR.L/lpr,  BXSB,  (NZW  x  BXSB)F1,  NZB/ 
KN, and KK-Ay mice (11-18),  and that the transplantation 
of a hemopoietic stem cell (HSC)-enriched population from 
autoimmune-prone mice to normal mice induces autoimmune 
diseases in normal mice (19).  These findings prompted us 
to examine whether BMT could be used to treat FGS and/or 
whether the transplantation of a HSC-enriched population 
from FGS mice to normal mice could induce FGS in normal 
mice. 
In this paper, we provide evidence that FGS, one type of 
intractable chronic glomerulonephritis, is a stem cell disorder. 
Materials and Methods 
Mice.  FGS mice were obtained from Nagoya University or Set- 
sunan University. BALB/c and C57BL/6 (B6) mice were purchased 
from CLEA Japan (Osaka). These mice were maintained under 
specific pathogen-free conditions in the animal facility at Kansai 
Medical University. 
BMT.  FGS (H-2k), BALB/c (H-2a), and B6 (H-2  s) mice were 
lethally irradiated from a 6~  source (8.5 Gy for FGS and BALB/c 
mice, and 9.5 Gy for B6 mice). FGS mice were reconstituted with 
intravenous injection of 107 T  cell-depleted bone marrow cells 
(TCD-BMCs) from BALB/c or B6 mice to treat the FGS. To in- 
duce FGS in normal mice, TCD-BMC (107) or an HSC-enriched 
population (106 Ft.2 cells or 10  s wheat germ agglutinin  [WGA] + 
cells) from young FGS mice (6-9 wk old) were transferred to ir- 
radiated B6 or BALB/c mice. The HSC-enriched population was 
prepared, as described below. 
Preparation of HSC-enriched Population.  To obtain an HSC-en- 
riched population, BMCs that had been depleted of T cells, B cells, 
and macrophages were fractionated by centrifugation using Percoll 
discontinuous density gradients to remove granulocytes. HSCs were 
enriched in Fr.2, as previously  described  (20). The Ft.2 cells (lineage- 
negative [Lin-] cells) were then stained using FITC-WGA (Poly- 
science Inc., Warrington,  PA), and the WGA + cells were sorted 
using a FACStar  |  (Becton Dickinson & Co., Mountain View, CA). 
Bone Grafts.  Femurs  and tibias, from which bone marrow cells 
had been flushed out, were grafted in the subcutis to recruit donor- 
derived stromal cells, as previously described (16, 17). 
Cytofluorometric Analyses.  H-2 typing was carried out using a 
FACScan  |  (Becton Dickinson & Co.), as previously described (19). 
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 Spleen cells suspended in PBS containing 2% FCS and 0.05% so- 
dium  azide were  stained with  FITC-conjugated  mAbs  against 
H-2D  b, H-2D  d, and H-2D  k. The mAbs were purchased from the 
Meiji Institute of Health Science (Odawara, Japan). 
Histological  Studies.  The kidneys were obtained by biopsy or 
autopsy. Sections were stained with hematoxylin/eosin (H-E). For 
immunofluorescence (IF) studies, organs were frozen using OCT 
compound (Tissue-Tek;  Miles Inc., Elkhart, IN). 3-#m sections were 
incubated  at  room  temperature  with  FITC-conjugated  rabbit 
anti-mouse IgG, IgM, IgA, or FITC-conjugated anti-mouse C3 
(Medical and Biological Laboratories, Nagoya, Japan). The fluores- 
cence intensity of  the IgG, IgM, IgA, and C3 deposits in the mesan- 
gial areas was graded as:  -, no visible deposits; _% weak deposits; 
+, slight deposits; + +, moderate deposits; + + +, strong deposits. 
Small blocks of the renal cortex were fixed in 2% glutaralde- 
hyde and then in 1% osmic acid. After being embedded in Epon 
812, ultra-thin  sections were prepared for EM studies. 
Autoantibodies.  Anti-ssDNA antibodies and rheumatoid factors 
(RF) were measured by an ELISA. Immunoplates (Nunc, Roskilde, 
Denmark)  were coated with heat-denatured  calf thymus  DNA 
(ssDNA) (Sigma Chemical Co., St. Louis, MO) at 50 #g/ml or 
goat IgG (Cappel Laboratories, West Chester, PA) at  10 #g/ml 
for 2-3 h at 37~  and further coated with 2% egg albumin-PBS 
(EA-PBS) overnight at 4~  to block nonspecific binding. Mouse 
sera were diluted 1:35 in EA-PBS  with 0.05% Tween 20 (EA-PBS- 
Tween). Diluted sera were added to wells and incubated for 1 h 
at room temperature. After washing in PBS-Tween,  wells were in- 
cubated for 1 h with alkaline phosphatase-labeled Ab specific for 
mouse IgM or IgG (Cappel Laboratories). After the addition of 
substrate, OD was determined with an automated spectrophotom- 
eter, and Ab activity was expressed as mean OD  _+ SD. Immune 
complexes in the sera were measured by a Clq-binding  assay using 
ELISA. Immunoplates were coated with human purified Clq (Sanko 
Junyaku Co., Ltd., Tokyo,  Japan) at 10 #g/ml, and postcoated with 
EA-PBS. Sera (5 #1) were incubated with 25/A 0.2 M EDTA for 
30 min at 37~  and 200/A EA-PBS-Tween  was added. Samples 
including aggregated mouse IgG as standards were added to Clq- 
coated plates, and the bound IgG was measured by alkaline phos- 
phatase-labeled anti-mouse IgG. Results were expressed as micro- 
grams per milliliter equivalent to aggregated mouse IgG. 
Each experiment included more than five mice. All experiments 
were repeated more than three times. Reproducible results were 
obtained, and representative  data are therefore shown in the figures. 
Results and Discussion 
We selected 3-5-mo-old FGS mice with severe proteinuria 
(+ + + ). Before BMT, we performed renal biopsy. Light mi- 
croscopic (LM) studies showed perivascular infiltration of lym- 
phocytes and plasma cells. The glomeruli exhibited solidifi- 
cation of one or more lobules of the tufts (Fig. 1 A). IF studies 
revealed granular deposits of IgG (+ + +), IgM (+ +), IgA 
(+),  and C3  (_+) in the mesangial areas  segmentally (Fig. 
1 B). In humans, IgM, usually in combination with C3, is 
commonly demonstrated in the segmental sclerotic areas, al- 
though IgG has also been recorded in segmental sclerotic areas 
(1, 21). EM studies demonstrated electron-dense materials in 
the mesangial matrix and paramesangial  subendothelium (Fig. 
1 C).  In addition, obliteration of capillary lumens and the 
effacement of foot processes were noted. 
The  FGS  (H-2  k)  mice  with  proteinuria  (+ + +)  were 
lethally (8.5 Gy) irradiated and then reconstituted with TCD- 
chimera-- 
AV-FITC  ~ ;"-i~ 
lit  t i= :i -- H-2 a 
tjl 
lJ  I,,  /1  :::i 
,;'  ~  H-2  k  j  ~  !: 
t~  141  1~2  1a2 
VL.I 
Figure 2.  H-2 typing in a (BALB/c  --,- FGS) mouse. Spleen  cells in a 
(BALB/c --* FGS) mouse are H-2  a positive. 
BMCs of BALB/c (H-2  a) mice with bone grafts (to recruit 
stromal cells), since we know that donor-derived stromal cells 
are necessary for reconstitution, particularly when the mice 
are radiosensitive, as previously reported in MRL/1pr and 
NZB/KN mice (16, 17). Proteinuria began to decrease 6 wk 
after the transplants and became almost undetectable after 
11 wk.  We killed these mice and carried out LM, IF,  and 
EM studies. The glomeruli showed normal appearance in LM 
studies  (Fig.  1 D).  IF  studies  revealed markedly reduced 
deposits of immunoglobulins such as IgG and IgM (Fig.  1 
E).  Electron-dense  materials  disappeared,  and  the  inter- 
digitating foot processes of the podocytes were noted, although 
there was still some proliferation of the mesangial matrix at 
this  stage  (Fig.  1  F).  Chimerism  was  evaluated  using  a 
FACScan |  Spleen cells  of FGS (H-2  ~) mice reconstituted 
with  BALB/c (H-2  a)  BMCs  were H-2  a positive (Fig.  2). 
Thus,  we succeeded in  treating FGS by BMT. 
The next step was to examine whether FGS could be in- 
(%) 
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1  2  3  4  5  6  7  8  91011121314151617181920 
Weeks  after BMT 
Figure 3.  The fate of (FGS ~  B6) chimeric  mice. (FGS  --~ B6) mice 
begin to show proteinuria  (+ +) from 7 wk after BMT and show severe 
proteniuria (+ + +) by 17 wk after BMT, followed  by death from renal 
failure by 20 wk. 
1055  Nishimura  et al.  Brief  Definitive Report Figure 4.  Histopathological  find- 
ings in the kidney  ofa (FGS  ~  B6) 
chimeric  mouse. (,4) Glomeruloscle- 
rosis is seen in a kidney of the 
(FGS--~ B6)  mouse 17 wk after 
BMT (x600). (B) lgG deposits are 
noted in  two  glomeruli of the 
mouse (x300). 
duced in normal mice by transplantation of BMCs from FGS 
mice.  B6 mice were lethally irradiated (9.5  Gy) and recon- 
stituted with 107 TCD-BMCs of FGS mice.  The (FGS --~ 
B6) mice began to show proteinuria (+ +) from 7 wk after 
BMT, and showed severe proteinuria (+ + +) by 17 wk after 
BMT, followed by death from renal failure by 20 wk (Fig. 
3).  Fig.  4  shows  the  histopathological  findings  in  the 
(FGS --* B6) mice. Swelling of glomeruli was observed 9 wk 
after BMT (data not shown), and glomerulosclerosis devel- 
oped 17 wk after BMT (Fig. 4 A). IgG deposits were found 
in the glomeruli (Fig. 4 B), and electron-dense materials were 
found in the basement membranes and also mesangial ma- 
trix 17 wk after BMT (data not shown). To provide evidence 
that FGS is, indeed, a stem cell disorder, we purified the HSCs 
of FGS mice, FGS developed also in the B6 mice reconstituted 
with  an  HSC-enriched  population  (106 Fr.2  cells  or  105 
WGA §  cells) of the FGS mice. 
Based on these findings, we conclude that FGS is a stem 
cell disorder.  Since we have shown that both systemic and 
organ-specific autoimmune diseases are stem cell disorders (18), 
we propose that FGS is an organ (kidney)-specific  autoim- 
mune disease. However, it remains to be resolved which au- 
1056  Focal Segmental  Glomerular Sclerosis Is a Stem Cell Disorder toantihodies are involved in the development of FGS. We have 
measured anti-DNA antibodies and circulating immune com- 
plexes in the sera of FGS mice, but have been unable to detect 
any significant difference  between normal and FGS mice (data 
not shown). 
A particular form of FGS recently has been described in 
patients with AIDS (22-24). It is well known that patients 
with AIDS develop autoimmune diseases. It is therefore con- 
ceivable that exogenous or endogenous viruses are involved 
in the development of  FGS. We are in the process of elucidating 
the abnormalities of HSCs in FGS at the molecular level. 
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